SCHEMBL23580504

SCHEMBL23580504

O=C(NC1CC1)c1ncc(N=C(c2ccccc2)c2ccccc2)cc1C(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ HTR4 Q13639 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ RIPK1 Q13546 1/20 0.36
▸ BRD4 O60885 2/20 0.36
▸ EGLN1 Q9GZT9 1/20 0.36
▸ ATR Q13535 2/20 0.36
▸ DGAT1 O75907 1/20 0.36
▸ MAPK8 P45983 1/20 0.36
▸ CYP46A1 Q9Y6A2 1/20 0.35
▸ HPGDS O60760 1/20 0.35
▸ AR P10275 2/20 0.35
▸ PKM P14618 1/20 0.35
▸ CKS1B P61024 1/20 0.35
▸ SKP1 P63208 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29882674 1.00 NPC1 (0.39) NPC1ALDH1A1L3MBTL1HTR4MEN1
SCHEMBL23580608 0.79 CCR3 (0.36) NPC1RAB9A
SCHEMBL29882638 0.79 CCR3 (0.36) NPC1RAB9A
SCHEMBL23608666 0.77 KMT2A (0.34) MEN1RAB9AKMT2ASMN1; SMN2EGLN1
SCHEMBL23580331 0.77 L3MBTL3 (0.39) ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL29882323 0.77 L3MBTL3 (0.39) ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL23608500 0.74 KMT2A (0.34) ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL23581042 0.74 HPGD (0.38) —
SCHEMBL23580207 0.74 SMYD3 (0.45) NPC1ALDH1A1MEN1RAB9AKMT2A
SCHEMBL24364780 0.72 ESR2 (0.36) ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 — — US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 — — US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 — — US disclosed
EP-4081526-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME Schrödinger, Inc. (US) 2022-11-02 — — EP disclosed
CN-114945571-A Cyclic compounds and methods of use thereof 薛定谔公司 2022-08-26 — — CN disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 — — WO disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A NPC1 445/4885ALDH1A1 2190/4885L3MBTL1 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback